title: Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer.
authors: Clinical Unit of Anesthesiology and Perioperative Intensive-Care Medicine, University of Veterinary Medicine, Vienna, Austria.
authors: Lidia
authors: L
authors: Kowalczyk
authors: Department of Obstetrics and Gynecology, Center for Breast Health, Medical University of Vienna, Vienna, Austria.
authors: Christian F
authors: CF
authors: Singer
authors: Department of Obstetrics and Gynecology, Center for Breast Health, Medical University of Vienna, Vienna, Austria.
authors: Christine
authors: C
authors: Staudigl
authors: Department of Obstetrics and Gynecology, Center for Breast Health, Medical University of Vienna, Vienna, Austria.
authors: Myriam
authors: M
authors: Weber
authors: Department of Obstetrics and Gynecology, Center for Breast Health, Medical University of Vienna, Vienna, Austria.
authors: Alex
authors: A
authors: Farr
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012871:Skin Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D003907:Dexamethasone; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C485206:pertuzumab